# Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

> **NCT01074021** · PHASE3 · UNKNOWN · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** placebo plus chemoradiotherapy

## Key facts

- **NCT ID:** NCT01074021
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-08
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074021, "Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01074021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*